Efficacy of systemic temozolomide‐activated phage‐targeted gene therapy in human glioblastoma
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Glioblastoma multiforme (GBM) is the most lethal primary intracranial malignant neoplasm in adults and most resistant to treatment. Integration of gene therapy and chemotherapy, chemovirotherapy, has the potential to improve treatment. We have introduced an intravenous bacteriophage (phage) vector for dual targeting of therapeutic genes to glioblastoma. It is a hybrid AAV/phage, AAVP, designed to deliver a recombinant adeno‐associated virus genome (rAAV) by the capsid of M13 phage. In this vector, dual tumor targeting is first achieved by phage capsid display of the RGD4C ligand that binds the αvβ3 integrin receptor. Second, genes are expressed from a tumor‐activated and temozolomide (TMZ)‐induced promoter of the glucose‐regulated protein, Grp78. Here, we investigated systemic combination therapy using TMZ and targeted suicide gene therapy by the RGD4C/AAVP‐Grp78. Firstly, in vitro we showed that TMZ increases endogenous Grp78 gene expression and boosts transgene expression from the RGD4C/AAVP‐Grp78 in human GBM cells. Next, RGD4C/AAVP‐Grp78 targets intracranial tumors in mice following intravenous administration. Finally, combination of TMZ and RGD4C/AAVP‐Grp78 targeted gene therapy exerts a synergistic effect to suppress growth of orthotopic glioblastoma. Following intravenous administration, the RGD4C/AAVP‐Grp78 vector delivers the therapeutic AAV genome into GBM via binding to integrins. Treatment with temozolomide (TMZ) induces the Grp78 promoter activity and subsequently the therapeutic gene expression resulting in synergistic anti‐tumor action. Following intravenous administration, the RGD4C/AAVP‐Grp78 vector delivers the therapeutic AAV genome into GBM via binding to integrins. Treatment with temozolomide (TMZ) induces the Grp78 promoter activity and subsequently the therapeutic gene expression resulting in synergistic anti‐tumor action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834 · cited 1×
“Even more recent trials with antiangiogenic and molecularly targeted therapies have shown only slight improvements in GBM outcome (Gilbert et al, 2014).”
ResultYu, Z., Luo, H., Fu, W., & Mattson, M. P. (1999) · Experimental Neurology · doi:10.1006/exnr.1998.7002 · Cited by 438
Integrin αvβ3 as a Therapeutic Target for Blocking Tumor-Induced Angiogenesis
Kumar, C. (2003) · Current Drug Targets · doi:10.2174/1389450033346830 · Cited by 280
Messaoudi, K., Clavreul, A., & Lagarce, F. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.011 · Cited by 238 · cited 1×
“Temozolomide (TMZ), an alkylating agent able to cross the blood–brain barrier (BBB), is welltolerated and widely used as part of standard chemotherapy for newly diagnosed and recurrent GBM, but has limited efficacy (Thon et al, 2013; Messaoudi et al, 2015; Taal et al, 2015).”
Background
Cited by
(2023) · doi:10.1016/j.mtbio.2023.100612 · Cited by 71
Bacteriophages as Solid Tumor Theragnostic Agents
Veeranarayanan, S., Azam, A. H., Kiga, K., Watanabe, S., & Cui, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010402 · Cited by 39
“Another striking feature of the phage display is the ability to exploit the bacteriophages to display certain peptides that could help in crossing biological barriers efficiently [74].”
BackgroundBacteriophage-Mediated Cancer Gene Therapy
Petrov, G., Dymova, M., & Richter, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214245 · Cited by 38
Bacteriophages as Targeted Therapeutic Vehicles: Challenges and Opportunities
Venkataraman, S., Shahgolzari, M., Yavari, A., & Hefferon, K. (2025) · Bioengineering · doi:10.3390/bioengineering12050469 · Cited by 38
Engineered Bacteriophage T7 as a Potent Anticancer Agent in vivo
Hwang, Y. J., & Myung, H. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.491001 · Cited by 31
Metadata
- Authors
- Przystal, J. M., Waramit, S., Pranjol, M. Z. I., Yan, W., Chu, G., Chongchai, A., Samarth, G., Olaciregui, N. G., Tabatabai, G., Carcaboso, A. M., Aboagye, E. O., Suwan, K., & Hajitou, A.
- Venue
- EMBO Molecular Medicine
- Published
- 2019-02-27
- Volume
- 11
- Issue
- 4
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2915820738
- Cited by
- 85
- References
- 4
- FWCI
- 5.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of systemic temozolomide‐activated phage‐targeted gene therapy in human glioblastoma. https://app.cochat.ai/papers/10.15252/emmm.201708492
- The paper
- Przystal, J. M., Waramit, S., Pranjol, M. Z. I., Yan, W., Chu, G., Chongchai, A., Samarth, G., Olaciregui, N. G., Tabatabai, G., Carcaboso, A. M., Aboagye, E. O., Suwan, K., & Hajitou, A. (2019). Efficacy of systemic temozolomide‐activated phage‐targeted gene therapy in human glioblastoma. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201708492
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.